Acute Myeloid Leukemia | CHOP Research Institute
 

Acute Myeloid Leukemia

Uproleselan in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Mixed Phenotype Acute Leukemia (MPAL)

Uproleselan in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Mixed Phenotype Acute Leukemia (MPAL)

This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back (‘relapsed’) or does not respond to therapy (‘refractory’).

AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia

This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R).

Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Relapsed AML

Fludarabine,Cytarabine,Gemtuzumab Ozogamicin With or Without Venetoclax in Relapsed AML

This study involves taking a study drug called venetoclax with or without standard of care chemotherapy.

Three CHOP Researchers Receive Doris Duke Foundation Research Awards

Published on
Oct 30, 2023
in Cornerstone Blog
Doris Duke Foundation Awards
Three researchers at CHOP received Doris Duke Foundation awards.

Scientists Target FLT3 Protein in New Approach for High-risk Childhood Leukemias

Published on
Sep 8, 2023
in Cornerstone Blog
Immunotherapy Target in Two High-risk Childhood Leukemias
Sarah K. Tasian, MD, received a $1 million grant to further her research into a novel immunotherapy for high-risk pediatric leukemias.

FLT3 CAR T-cell Immunotherapy, Lymphatic Conference, Cellicon Valley, Pediatric Heatstroke

Published on
Jul 7, 2023
in Cornerstone Blog
In the News: Lymphatic Conference and Cellicon Valley Highlights
See highlights from the Third Annual Lymphatic Disorder Conference and Cellicon Valley ’23, and more in this week’s research news roundup.

Do RAB Proteins Play a Role in Development of Acute Myeloid Leukemia?

Published on
Jun 22, 2023
in Cornerstone Blog
Protein Linked to AML
Wei Tong, PhD, and colleagues found a protein interaction that appears to be a driver of hematologic malignancies.

Outstanding Science Award, Highly Cited Researcher, STAT Wunderkinds

Published on
Dec 9, 2022
in Cornerstone Blog
In the News
This week's news roundup features an outstanding science award, Highly Cited Researchers, and STAT Wunderkinds, along with new research about cancer risk with birth defects, epilepsy, and acute myeloid leukemia.

Taking CAR T-Cell Therapy to Solid Tumors and Beyond

Published on
Sep 19, 2022
in Cornerstone Blog
Where Discovery Leads: CAR T-Cell Therapy Research
CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

AAML1921; Bosutinib for Chronic Myeloid Leukemia

The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).